Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Amylyx Pharmaceuticals Inc shares valued at $1,850,795 were sold by Cohen Joshua B on Jan 15 ’26. At $13.59 per share, Cohen Joshua B sold 136,193 shares. The insider’s holdings dropped to 3,378,621 shares worth approximately $54.84 million following the completion of this transaction.
Also, Cohen Joshua B sold 1,974 shares, netting a total of over 27,299 in proceeds. Following the sale of shares at $13.83 each, the insider now holds 3,379,465 shares.
Before that, Klee Justin B. had sold 136,193 shares from its account. In a trade valued at $1,849,869, the Co-Chief Executive Officer traded Amylyx Pharmaceuticals Inc shares for $13.58 each. Upon closing the transaction, the insider’s holdings decreased to 136,193 shares, worth approximately $54.83 million.
Analysts at Guggenheim started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. As of June 17, 2025, Citigroup has initiated its “Buy” rating for AMLX. Earlier on May 30, 2025, TD Cowen initiated its rating. Their recommendation was “a Buy” for AMLX stock.
Analyzing AMLX Stock Performance
On last trading session, Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] plunged -4.08% to $16.23. The stock’s lowest price that day was $16.14, but it reached a high of $17.49 in the same session. During the last five days, there has been a surge of approximately 15.35%. Over the course of the year, Amylyx Pharmaceuticals Inc shares have jumped approximately 370.43%.
Is Amylyx Pharmaceuticals Inc subject to short interest?
Stocks of Amylyx Pharmaceuticals Inc saw a sharp rise in short interest on 2025-12-31 jumping by 2.02 million shares to 13.64 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 11.62 million shares. A jump of 14.8% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.22 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.22.
Which companies own the most shares of Amylyx Pharmaceuticals Inc (AMLX)?
In terms of Amylyx Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 19 in the next 12 months, up nearly 12.29% from the previous closing price of $16.92. Analysts anticipate Amylyx Pharmaceuticals Inc stock to reach 25 by 2026, with the lowest price target being 16. In spite of this, 3 analysts ranked Amylyx Pharmaceuticals Inc stock as Buy at the end of 2026. On April 07, 2025, Mizuho assigned a price target of “an Outperform” to the stock and upgraded coverage with a $7.
